| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/15/2023 | 231.13% | Needham | → $5 | Reiterates | Buy → Buy |
| 07/25/2023 | 231.13% | Needham | $6 → $5 | Maintains | Buy |
| 05/12/2023 | 297.35% | Needham | $7 → $6 | Maintains | Buy |
| 04/21/2023 | 363.58% | Needham | → $7 | Reiterates | → Buy |
| 03/24/2023 | 562.25% | Evercore ISI Group | $15 → $10 | Maintains | Outperform |
| 03/24/2023 | 363.58% | Needham | $8 → $7 | Maintains | Buy |
| 11/09/2022 | 429.8% | Needham | $10 → $8 | Maintains | Buy |
| 06/30/2022 | 562.25% | Needham | $14 → $10 | Maintains | Buy |
| 05/10/2022 | 827.15% | Needham | $16 → $14 | Maintains | Buy |
| 12/02/2020 | 1489.4% | SVB Leerink | $21 → $24 | Maintains | Outperform |
| 05/27/2020 | 1489.4% | Guggenheim | → $24 | Initiates Coverage On | → Buy |
| 03/02/2020 | 2813.91% | Needham | $48 → $44 | Maintains | Buy |
| 02/20/2020 | 3078.81% | Needham | $50 → $48 | Maintains | Buy |
| 10/03/2019 | 2019.21% | JMP Securities | $38 → $32 | Reiterates | → Market Outperform |
| 09/14/2018 | 3542.38% | Stifel | → $55 | Initiates Coverage On | → Buy |
What is the target price for Heron Therapeutics (HRTX)?
The latest price target for Heron Therapeutics (NASDAQ: HRTX) was reported by Needham on August 15, 2023. The analyst firm set a price target for $5.00 expecting HRTX to rise to within 12 months (a possible 231.13% upside). 7 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Heron Therapeutics (HRTX)?
The latest analyst rating for Heron Therapeutics (NASDAQ: HRTX) was provided by Needham, and Heron Therapeutics reiterated their buy rating.
When is the next analyst rating going to be posted or updated for Heron Therapeutics (HRTX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Heron Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Heron Therapeutics was filed on August 15, 2023 so you should expect the next rating to be made available sometime around August 15, 2024.
Is the Analyst Rating Heron Therapeutics (HRTX) correct?
While ratings are subjective and will change, the latest Heron Therapeutics (HRTX) rating was a reiterated with a price target of $0.00 to $5.00. The current price Heron Therapeutics (HRTX) is trading at is $1.51, which is within the analyst's predicted range.